查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1692191

細胞重編程市場 - 全球產業規模、佔有率、趨勢、機會和預測，按技術、應用、最終用戶、地區和競爭細分，2020-2030 年預測

Cell Reprogramming Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球細胞重編程市場價值為 3.2545 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 8.14%。細胞重編程已成為生物技術和再生醫學領域的革命性領域。它有望將普通細胞轉化為多能幹細胞或直接將一種細胞類型轉化為另一種細胞類型，為疾病建模、藥物發現和再生療法提供前所未有的機會。在技​​術進步、研究資金增加以及對創新醫療保健解決方案的需求不斷成長的推動下，全球細胞重編程市場一直穩步成長。

市場概況
預測期 2026-2030
2024 年市場規模 3.2545 億美元
2030 年市場規模 5.1635億美元
2025-2030 年複合年成長率 8.14％
成長最快的領域 mRNA重編程
最大的市場 北美洲

細胞重編程涉及將成熟的、專門的細胞轉化為更原始的狀態，通常類似於胚胎幹細胞。這個過程可以透過各種技術實現，其中最著名的是誘導多能幹細胞 (iPSC) 重編程和直接譜系轉換。 iPSC 重編程使科學家能夠提取成體細胞並重撥其發育時鐘，使其具有多能性並能夠分化為各種細胞類型。相較之下，直接譜系轉換跳過了多能階段，直接將一種細胞類型轉化為另一種細胞類型，例如將皮膚細胞轉化為神經元。

全球細胞重編程市場受到多種多樣的應用所推動。細胞重編程有可能徹底改變再生醫學，因為它能夠創造出患者特定的、有功能的移植細胞，從而降低排斥風險。研究人員可以利用多能幹細胞創建針對特定疾病的細胞系，從而研究各種疾病的分子機制並篩選潛在的候選藥物。細胞重編程在藥物篩選和毒性測試中起著至關重要的作用，減少了動物測試的需要並加速了藥物開發。多能幹細胞可以從個別患者體內產生，從而可以製定個人化的療法和治療計劃。

主要市場促進因素

慢性病盛行率上升推動全球細胞重編程市場

主要市場挑戰

技術複雜性

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球細胞重編程市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依技術分類（基於仙台病毒、mRNA 重編程、其他）
    • 按應用（研究、治療）
    • 按最終用戶（研究和學術機構、生物技術和製藥公司、醫院和診所、其他）
    • 按地區
    • 按公司分類（前五大市場參與者的佔有率，2024 年）
  • 市場地圖
    • 依技術分類
    • 按應用
    • 按最終用戶
    • 按地區

第6章：北美細胞重編程市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第 7 章：歐洲細胞重編程市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第 8 章：亞太地區細胞重編程市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第9章：南美細胞重編程市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第 10 章：中東和非洲細胞重編程市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 合併與收購
  • 技術發布

第 13 章：競爭格局

  • Allele Biotechnology co. ltd.
  • ALSTEM, INC
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Fujifilm Cellular Dynamics inc.
  • Lonza Group AG
  • Mogrify inc.
  • REPROCELL Inc.
  • Stemnovate Limited
  • Thermo Fisher Scientific Inc.

第 14 章：策略建議

第15章調查會社について,免責事項

簡介目錄
Product Code: 17395

The Global Cell Reprogramming Market was valued at USD 325.45 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.14% through 2030. Cell reprogramming has emerged as a revolutionary field in biotechnology and regenerative medicine. It holds the promise of transforming ordinary cells into pluripotent stem cells or directly converting one cell type into another, offering unprecedented opportunities for disease modeling, drug discovery, and regenerative therapies. The global cell reprogramming market has been steadily growing, driven by advancements in technology, increasing research funding, and a growing demand for innovative healthcare solutions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 325.45 Million
Market Size 2030USD 516.35 Million
CAGR 2025-20308.14%
Fastest Growing Segmentm RNA Reprogramming
Largest MarketNorth America

Cell reprogramming involves the conversion of mature, specialized cells into a more primitive state, often akin to embryonic stem cells. This process can be achieved through various techniques, with the most well-known being induced pluripotent stem cell (iPSC) reprogramming and direct lineage conversion. iPSC reprogramming allows scientists to take adult cells and rewind their developmental clock, making them pluripotent and capable of differentiating into various cell types. In contrast, direct lineage conversion skips the pluripotent stage, directly converting one cell type into another, such as turning skin cells into neurons.

The global cell reprogramming market is driven by a diverse range of applications. Cell reprogramming has the potential to revolutionize regenerative medicine by enabling the creation of patient-specific, functional cells for transplantation, thereby reducing the risk of rejection. Researchers can use pluripotent stem cell to create disease-specific cell lines, allowing them to study the molecular mechanisms of various diseases and screen potential drug candidates. Cell reprogramming plays a crucial role in drug screening and toxicity testing, reducing the need for animal testing and accelerating drug development. Pluripotent stem cell can be generated from individual patients, enabling the development of personalized therapies and treatment plans.

Key Market Drivers

Rising Prevalence of Chronic Diseases is Driving the Global Cell Reprogramming Market

The global healthcare landscape is witnessing a paradigm shift as chronic diseases continue to rise in prevalence. Diseases such as diabetes, cardiovascular disorders, neurodegenerative conditions, and cancer have become increasingly common, posing a significant challenge to healthcare systems worldwide. In response to this growing health crisis, the field of cell reprogramming is emerging as a promising frontier for addressing chronic diseases. The global cell reprogramming market is gaining momentum as researchers and biotechnology companies explore innovative ways to harness the regenerative potential of cells. For instance, the International Agency for Research on Cancer (IARC) projects that by 2040, the global cancer burden will rise to 27.5 million new cases and 16.3 million cancer-related deaths, largely due to population growth and aging. Additionally, an August 2022 article in the Radiation journal featured research by a Kindai University scientist in Japan exploring the optimal use of Radium-223 therapy for Metastatic Castration-Resistant Prostate Cancer. The study indicated that early administration of Ra-223 significantly improved overall survival (OS), highlighting potential advantages of using Ra-223 before novel hormonal or anticancer treatments.

Key Market Challenges

Technical Complexity

One of the primary challenges in the field of cell reprogramming is the technical complexity involved in generating high-quality iPSCs. Reprogramming adult cells into pluripotent stem cells is a delicate process that requires precise manipulation of cellular factors. Researchers must carefully select reprogramming methods, optimize culture conditions, and monitor cell differentiation to ensure the reliability and safety of iPSCs. This technical complexity not only demands considerable expertise but also makes the production of iPSCs time-consuming and costly.

Key Market Trends

Technological Advancements

The field of regenerative medicine has been revolutionized in recent years, thanks to significant advancements in cell reprogramming technology. Cell reprogramming, a process that involves resetting the identity of mature cells to a pluripotent state, has opened new avenues for the treatment of various diseases and the development of personalized medicine. As technological innovations continue to accelerate, the global cell reprogramming market is experiencing unprecedented growth. The advent of CRISPR-Cas9 technology has significantly enhanced the precision and efficiency of cell reprogramming. Researchers can now edit specific genes within cells, eliminating potential genetic mutations that may hinder the successful reprogramming process. This innovation has accelerated the production of high-quality iPSCs for various applications.

Automation systems and high-throughput screening platforms have streamlined the cell reprogramming process. This allows for the rapid generation of iPSCs in larger quantities, making them more accessible for research and clinical use. Automated systems also reduce the risk of contamination and human error, ensuring consistent and reliable results. Technological advancements in 3D bioprinting and the development of organoids have expanded the possibilities of cell reprogramming. These techniques enable the creation of complex, tissue-like structures from iPSCs, paving the way for more advanced disease modeling and drug testing. Artificial intelligence and machine learning algorithms have become integral in analyzing and interpreting large datasets generated from cell reprogramming experiments. These tools help identify novel factors and pathways involved in reprogramming, leading to more efficient and targeted approaches. Traditional methods of introducing reprogramming factors into cells often relied on viral vectors, which carried risks of genomic integration and mutagenesis. Non-viral delivery systems, such as synthetic RNA and protein-based approaches, have emerged as safer alternatives, improving the overall safety profile of cell reprogramming.

The global cell reprogramming market is witnessing remarkable growth, driven by these technological advancements and their applications. Pharmaceutical companies are increasingly investing in iPSC-based drug discovery and toxicity testing, while academic institutions are using iPSCs to study various diseases, including neurodegenerative disorders, heart disease, and cancer. Furthermore, the field of regenerative medicine is moving closer to the realization of personalized therapies. iPSCs derived from a patient's own cells can be reprogrammed and differentiated into specific cell types, offering the potential for individualized treatments and reduced risk of immune rejection.

Key Market Players

  • Allele Biotechnology co. ltd.
  • ALSTEM, INC
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Fujifilm Cellular Dynamics inc.
  • Lonza Group AG
  • Mogrify inc.
  • REPROCELL Inc.
  • Stemnovate Limited
  • Thermo Fisher Scientific Inc

Report Scope:

In this report, the Global Cell Reprogramming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Reprogramming Market, By Technology:

  • Sendai Virus-based
  • mRNA Reprogramming
  • Others

Cell Reprogramming Market, By Application:

  • Research
  • Therapeutic

Cell Reprogramming Market, By End user:

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics
  • Others

Cell Reprogramming Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Reprogramming Market.

Available Customizations:

Global Cell Reprogramming market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Reprogramming Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Sendai Virus-based, mRNA Reprogramming, Others)
    • 5.2.2. By Application (Research, Therapeutic)
    • 5.2.3. By End user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (Shares of Top 5 Market Players, 2024)
  • 5.3. Market Map
    • 5.3.1. By Technology
    • 5.3.2. By Application
    • 5.3.3. By End user
    • 5.3.4. By Region

6. North America Cell Reprogramming Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By End user
    • 6.2.4. By Country
      • 6.2.4.1. United States Cell Reprogramming Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Technology
        • 6.2.4.1.2.2. By Application
        • 6.2.4.1.2.3. By End user
      • 6.2.4.2. Canada Cell Reprogramming Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Technology
        • 6.2.4.2.2.2. By Application
        • 6.2.4.2.2.3. By End user
      • 6.2.4.3. Mexico Cell Reprogramming Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Technology
        • 6.2.4.3.2.2. By Application
        • 6.2.4.3.2.3. By End user

7. Europe Cell Reprogramming Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By End user
    • 7.2.4. By Country
      • 7.2.4.1. France Cell Reprogramming Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Technology
        • 7.2.4.1.2.2. By Application
        • 7.2.4.1.2.3. By End user
      • 7.2.4.2. Germany Cell Reprogramming Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Technology
        • 7.2.4.2.2.2. By Application
        • 7.2.4.2.2.3. By End user
      • 7.2.4.3. United Kingdom Cell Reprogramming Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Technology
        • 7.2.4.3.2.2. By Application
        • 7.2.4.3.2.3. By End user
      • 7.2.4.4. Italy Cell Reprogramming Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Technology
        • 7.2.4.4.2.2. By Application
        • 7.2.4.4.2.3. By End user
      • 7.2.4.5. Spain Cell Reprogramming Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Technology
        • 7.2.4.5.2.2. By Application
        • 7.2.4.5.2.3. By End user

8. Asia Pacific Cell Reprogramming Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End user
    • 8.2.4. By Country
      • 8.2.4.1. China Cell Reprogramming Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Technology
        • 8.2.4.1.2.2. By Application
        • 8.2.4.1.2.3. By Technology
      • 8.2.4.2. India Cell Reprogramming Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Technology
        • 8.2.4.2.2.2. By Application
        • 8.2.4.2.2.3. By End user
      • 8.2.4.3. South Korea Cell Reprogramming Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Technology
        • 8.2.4.3.2.2. By Application
        • 8.2.4.3.2.3. By End user
      • 8.2.4.4. Japan Cell Reprogramming Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Technology
        • 8.2.4.4.2.2. By Application
        • 8.2.4.4.2.3. By End user
      • 8.2.4.5. Australia Cell Reprogramming Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Technology
        • 8.2.4.5.2.2. By Application
        • 8.2.4.5.2.3. By End user

9. South America Cell Reprogramming Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By End user
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Cell Reprogramming Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Technology
        • 9.2.4.1.2.2. By Application
        • 9.2.4.1.2.3. By End user
      • 9.2.4.2. Argentina Cell Reprogramming Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Technology
        • 9.2.4.2.2.2. By Application
        • 9.2.4.2.2.3. By End user
      • 9.2.4.3. Colombia Cell Reprogramming Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Technology
        • 9.2.4.3.2.2. By Application
        • 9.2.4.3.2.3. By End user

10. Middle East & Africa Cell Reprogramming Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By End user
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Cell Reprogramming Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Technology
        • 10.2.4.1.2.2. By Application
        • 10.2.4.1.2.3. By End user
      • 10.2.4.2. Saudi Arabia Cell Reprogramming Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Technology
        • 10.2.4.2.2.2. By Application
        • 10.2.4.2.2.3. By End user
      • 10.2.4.3. UAE Cell Reprogramming Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Technology
        • 10.2.4.3.2.2. By Application
        • 10.2.4.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Technology Launches

13. Competitive Landscape

  • 13.1. Allele Biotechnology co. ltd.
  • 13.2. ALSTEM, INC
  • 13.3. Applied Biological Materials Inc.
  • 13.4. Axol Bioscience Ltd.
  • 13.5. Fujifilm Cellular Dynamics inc.
  • 13.6. Lonza Group AG
  • 13.7. Mogrify inc.
  • 13.8. REPROCELL Inc.
  • 13.9. Stemnovate Limited
  • 13.10.Thermo Fisher Scientific Inc.

14. Strategic Recommendations

15. About us & Disclaimer